[
  {
    "ts": "2025-06-16T20:21:03+00:00",
    "headline": "Supernus Pharmaceuticals Snaps Up Beleaguered Sage Therapeutics",
    "summary": "Supernus Pharmaceuticals agreed Monday to buy beleaguered biotech Sage Therapeutics in a deal that bolsters its nonpsychiatric portfolio.",
    "url": "https://www.investors.com/news/technology/sage-therapeutics-takeover-supernus-pharmaceuticals/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "f1f49aa5-aed4-3e16-bac9-04190635cef8",
      "content": {
        "id": "f1f49aa5-aed4-3e16-bac9-04190635cef8",
        "contentType": "STORY",
        "title": "Supernus Pharmaceuticals Snaps Up Beleaguered Sage Therapeutics",
        "description": "",
        "summary": "Supernus Pharmaceuticals agreed Monday to buy beleaguered biotech Sage Therapeutics in a deal that bolsters its nonpsychiatric portfolio.",
        "pubDate": "2025-06-16T20:21:03Z",
        "displayTime": "2025-06-16T20:21:03Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/f1f49aa5-aed4-3e16-bac9-04190635cef8/supernus-pharmaceuticals.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/68f07dfc6c90f9ef93a88aa7dad8ecc4",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uLdVBPHo8ae22FUuBonIWg--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/68f07dfc6c90f9ef93a88aa7dad8ecc4.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/k3l9UTG1eFeqf1KJDJyhSw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/68f07dfc6c90f9ef93a88aa7dad8ecc4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/sage-therapeutics-takeover-supernus-pharmaceuticals/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "SAGE"
            },
            {
              "symbol": "SUPN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-06-16T15:43:30+00:00",
    "headline": "Supernus makes depression drug play with $795m Sage buyout",
    "summary": "After Biogen failed with a takeover bid in January, Supernus has swooped in to acquire the postpartum depression pill developer.",
    "url": "https://www.pharmaceutical-technology.com/news/supernus-makes-depression-drug-play-with-795m-sage-buyout/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "c04b083e-9452-3029-9ffb-068316b6fd88",
      "content": {
        "id": "c04b083e-9452-3029-9ffb-068316b6fd88",
        "contentType": "STORY",
        "title": "Supernus makes depression drug play with $795m Sage buyout",
        "description": "",
        "summary": "After Biogen failed with a takeover bid in January, Supernus has swooped in to acquire the postpartum depression pill developer.",
        "pubDate": "2025-06-16T15:43:30Z",
        "displayTime": "2025-06-16T15:43:30Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/b22c45f2ae670ff27a13321eb32aed65",
          "originalWidth": 1000,
          "originalHeight": 750,
          "caption": "The latest round of layoffs will see Sage reduce 33% of its total workforce. Credits: Wirestock Creators/Shutterstock.com",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xHPL5laoyU7y8zHjb94RHw--~B/aD03NTA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/b22c45f2ae670ff27a13321eb32aed65.cf.webp",
              "width": 1000,
              "height": 750,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aB_Cvzuho8oLuMRdW_MEWA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/b22c45f2ae670ff27a13321eb32aed65.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/supernus-makes-depression-drug-play-with-795m-sage-buyout/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/supernus-makes-depression-drug-play-154330772.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SAGE"
            },
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "SUPN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-06-16T12:17:00+00:00",
    "headline": "Sage, following setbacks, to sell to Supernus for $561M",
    "summary": "In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per share, plus non-guaranteed additional payouts, after a series of stumbles that depressed its stock price.",
    "url": "https://www.biopharmadive.com/news/sage-therapeutics-acquired-supernus-deal-zurzuvae/750790/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "527a874f-75b1-3031-ab68-4c589723ed9a",
      "content": {
        "id": "527a874f-75b1-3031-ab68-4c589723ed9a",
        "contentType": "STORY",
        "title": "Sage, following setbacks, to sell to Supernus for $561M",
        "description": "",
        "summary": "In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per share, plus non-guaranteed additional payouts, after a series of stumbles that depressed its stock price.",
        "pubDate": "2025-06-16T12:17:00Z",
        "displayTime": "2025-06-16T12:17:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/ab9c2c6a68508e1de163287ee7c32402",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "Investors expect another lackluster year in IPOs and dealmaking, while company restructurings are likely to continue as biotech executives try to conserve cash.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TwZoNQuRoim.JXrZaEdmzw--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/ab9c2c6a68508e1de163287ee7c32402.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/R1trXTHgyUzvaunjznYj5A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/ab9c2c6a68508e1de163287ee7c32402.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/sage-therapeutics-acquired-supernus-deal-zurzuvae/750790/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sage-following-setbacks-sell-supernus-121700809.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SAGE"
            },
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]